358 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 Kang S, Rabbani Z, Folz R et al. Overexpression of extracellular super- oxide dismutase protects mice from radiation induced lung injury. Int J Radiat Oncol Biol Phys 2002;54:78. Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor ß on bleomycin induced accumulation of lung collagen in mice. Thorax 1993;48:959 –966. Daniels CE, Wilkes MC, Edens M et al. Imatinib mesylate inhibits the pro- fibrogenic activity of TGF- and prevents bleomycin-mediated lung fi- brosis. J Clin Invest 2004;114:1308 –1316. Anscher MS, Crocker IR, Jirtle RL. Transforming growth factor-beta 1 expression in irradiated liver. Radiat Res 1990;122:77– 85. Franko AJ, Sharplin J, Ghahary A et al. Immunohistochemical localiza- tion of transforming growth factor beta and tumor necrosis factor alpha in the lungs of fibrosis-prone and “non-fibrosing” mice during the latent pe- riod and early phase after irradiation. Radiat Res 1997;147:245–256. Liguang C, Larrier N, Rabbani ZN et al. Assessment of the protective ef- fect of keratinocyte growth factor on radiation-induced pulmonary toxic- ity in rats. Int J Radiat Oncol Biol Phys 2003;57:S162. Andarawewa KL, Paupert J, Pal A et al. New rationales for using TGF inhibitors in radiotherapy. Int J Radiat Biol 2007;83:803– 811. Portess DI, Bauer G, Hill MA et al. Low-dose irradiation of nontrans- formed cells stimulates the selective removal of precancerous cells via in- tercellular induction of apoptosis. Cancer Res 2007;67:1246 –1253. Flanders KC, Sullivan CD, Fujii M et al. Mice lacking Smad3 are pro- tected against cutaneous injury induced by ionizing radiation. Am J Pathol 2002;160:1057–1068. Peters CA, Stock RG, Cesaretti JA et al. TGFB1 single nucleotide poly- morphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2008;70: 752–759. Anscher MS, Peters WP, Reisenbichler H et al. Transforming growth fac- tor beta as a predictor of liver and lung fibrosis after autologous bone mar- row transplantation for advanced breast cancer. N Engl J Med 1993;328: 1592–1598. Kong FM, Anscher MS, Murase T et al. Elevated plasma transforming growth factor beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995;222:155–162. Kong F-M, Anscher M, Xiong Z et al. Elevated circulating transforming growth factor 1 levels decreased after radiotherapy in patients with lung cancer, cervical cancer and Hodgkin’s disease: A possible tumor marker. Int J Radiat Oncol Biol Phys 1995;32(suppl 1):239. Novakova-Jiresova A, Van Gameren MM, Coppes RP et al. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. Radiother Oncol 2004;71:183–189. De Jaeger K, Seppenwoolde Y, Kampinga HH et al. Significance of plasma transforming growth factor-beta levels in radiotherapy for non- small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;58:1378 –1387. Anscher MS, Kong FM, Andrews K et al. Plasma transforming growth factor 1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 1998;41:1029 –1035. Anscher MS, Kong FM, Marks LB et al. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radi- ation-induced pneumonitis. Int J Radiat Oncol Biol Phys 1997;37:253– 258. Anscher MS, Murase T, Prescott DM et al. Changes in plasma TGF beta levels during pulmonary radiotherapy as a predictor of the risk of devel- oping radiation pneumonitis. Int J Radiat Oncol Biol Phys 1994;30:671– 676. 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 Targeting TGF- 1 to Prevent Complications Kong FM, Ao X, Wang L et al. The use of blood biomarkers to predict radiation lung toxicity: A potential strategy to individualize thoracic radi- ation therapy. Cancer Control 2008;15:140 –150. Fu XL, Huang H, Bentel G et al. Predicting the risk of symptomatic radi- ation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. Int J Radiat Oncol Biol Phys 2001;50:899 –908. Anscher MS, Marks LB, Shafman TD et al. Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose esca- lation. J Clin Oncol 2001;19:3758 –3765. Anscher MS, Marks LB, Shafman TD et al. Risk of long-term complica- tions after TGF- 1-guided very-high-dose thoracic radiotherapy. Int J Ra- diat Oncol Biol Phys 2003;56:988 –995. Teicher BA. Malignant cells, directors of the malignant process: Role of transforming growth factor-beta. Cancer Metastasis Rev 2001;20:133– 143. Bierie B, Moses HL. Tumour microenvironment: TGF : The molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006;6:506 –520. Beck C, Schreiber H, Rowley D. Role of TGF- in immune-evasion of cancer. Microsc Res Tech 2001;52:387–395. Shariat SF, Kattan MW, Traxel E et al. Association of pre- and postoper- ative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 2004;10:1992–1999. Shariat SF, Walz J, Roehrborn CG et al. Early postoperative plasma trans- forming growth factor- 1 is a strong predictor of biochemical progression after radical prostatectomy. J Urol 2008;179:1593–1597. Wikström P, Damber J, Bergh A. Role of transforming growth factor- 1 in prostate cancer. Microsc Res Tech 2001;52:411– 419. Muraoka-Cook RS, Kurokawa H, Koh Y et al. Conditional overexpres- sion of active transforming growth factor 1 in vivo accelerates metasta- ses of transgenic mammary tumors. Cancer Res 2004;64:9002–9011. Muraoka RS, Dumont N, Ritter CA et al. Blockade of TGF- inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002;109:1551–1559. Bandyopadhyay A, Agyin JK, Wang L et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res 2006;66:6714 – 6721. Teicher BA, Ikebe M, Ara G et al. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: Reversal by decorin. In Vivo 1997;11:463– 472. Teicher BA, Holden SA, Ara G et al. Transforming growth factor-beta in in vivo resistance. Cancer Chemother Pharmacol 1996;37:601– 609. Kong F, Anscher M, Sporn T et al. Loss of mannose 6-phosphate/insulin- like growth factor receptor (M6P/IGF2R) may lead to an elevated trans- forming growth factor 1 (TGF 1) in circulation. Presented at the 45th Annual Meeting of the Radiation Research Society, Providence, RI, May 3–7, 1997. Dennis PA, Rifkin DB. Cellular activation of latent transforming growth factor ß requires binding to the cation-independent mannose 6-phosphate/ insulin-like growth factor type II receptor. Proc Natl Acad Sci U S A 1991; 88:580 –584. Anscher M, Kong F, Sporn T et al. Loss of a normally functioning man- nose 6-phosphate/insulin-like growth factor 2 receptor may lead to an el- evated plasma transforming growth factor ß1 level: Clinical implications. Presented at the 9th Lorne Cancer Conference, Victoria, Australia, Feb- ruary 13–16, 1997.